Start Date: 01/09/2021
End Date: 28/02/2027
Coordinator: European Vaccine Initiative (EVI)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007799. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Inno4vac partners:
European Vaccine Initiative, DE
Sclavo Vaccines Association, IT
2-control ApS, DK
Stichting Centre for Human Drug Research, NL
Eberhard Karls Universität Tübingen, DE
Enpicom BV, NL
Forschungszentrum Jülich GmbH, DE
Helmholtz Center for Infection Research GmbH, DE
Imperial College of Science Technology and Medicine London, UK
Insilico Biotechnology AG, DE
Instituto de Engenhariade Sistemas e Computadores, Tecnologia e Ciencia, PT
Association Internationales de Standardisation Biologique pour L´Europe, FR
Academisch Ziekenhuis Leiden, NL
Lunds Universitet, Department of Chemical Engineering, SE
Meyer Chroma Technology APS, DK
Medicines and Healthcare Products Regulatory Agency, UK
Rijksinstituut voor Volksgezondheid en Milieu, NL
Paul-Ehrlich-Institut, DE
Pharmalex Belgium, BE
Sciensano, BE
Danmarks Tekniske Universitet, DK
Nova ID FCT – Associação para a Inovação e Desenvolvimento de FCT, PT
University College London, UK
Universitätsklinikum Jena, DE
Klinikum der Universität zu Köln, DE
Academisch Ziekenhuis Groningen, NL
Universitetet I Bergen, NO
Goeteborgs Universitet, SE
The University of Nottingham, UK
Universitetet I Oslo, NO
The Chancellor, Masters and Scholars of the University of Oxford, UK
Universita Degli Studi di Siena, IT
Stiftung Tierärztliche Hochschule Hannover, DE
Julius-Maximilians-Universität Würzburg, DE
Universiteit Utrecht, NL
Viroclinics Biosciences BV, NL
VisMederi SRL, IT
GlaxoSmithKline Biologicals SA, BE
Sanofi Pasteur SA, FR
Takeda Pharmaceuticals International AG, CH
CureVac AG, DE